Highlights Previous influenza vaccination was associated with a reduced need for hospitalization after COVID-19 diagnosis. In 60 days of outpatient setting, four deaths occurred (three in the hospitalized and one in the non-hospitalized group). The persistence of more than two symptoms in 60 days was observed in 31.9% of patients. ABSTRACT Objective: To evaluate deaths, hospitalizations, and persistence of symptoms in patients with COVID-19 after infection in an outpatient setting during the first COVID-19 wave in Brazil. Methods: This prospective
The present systematic review and meta-analysis aimed to investigate the use of recombinant proteins to diagnose STIs and evaluate the performance of the tests identified. The databases, SciELO, PubMed, CAPES Journal Portal, and LILACS, were searched according to the PRISMA protocol. A study was considered eligible if it met previously defined criteria. The risk of study bias was assessed according to the QUADAS-2 protocol. The meta-analysis was performed based on the random-effects model, and heterogeneity was quantified using the I² statistic. A total of 1,355 studies were selected, 30 of which were relevant to the following: human immunodeficiency virus (12/30), Treponema pallidum (10/30), Chlamydia trachomatis (3/30), herpes simplex virus (HSV, 2/30), Trichomonas vaginalis (2/30), and HSV/cytomegalovirus (1/30). The main serological tests were ELISA and immunochromatography. The risk of bias was low for most included studies. According to each microorganism, the meta-analysis revealed satisfactory sensitivity and specificity for the analyzed tests. The findings reinforce the relevance of diagnostic tests based on recombinant proteins as viable alternatives for production and inclusion in clinical practice. PROSPERO registration number: CRD42020206331.
16 January 2022 in Research, Society and Development
A high number of women are exposed to antidepressants during pregnancy. Considering that an association between exposure to antidepressants and type 2 diabetes was found in the general population and pregnant women are inherently susceptible to insulin resistance, this study aimed to investigate data in the scientific literature on the association between antidepressant use during pregnancy and the risk of developing gestational diabetes mellitus (GDM). This systematic review was conducted according to the PRISMA guidelines. PubMed, Virtual Health Library (VHS), and Web of Science databases were searched to identify observational studies reporting the association between antidepressant use during pregnancy and GDM. Review articles, case reports, case series, clinical trials, and animal studies were excluded. In total, 67 studies were retrieved, of which 3 were included in the systematic review: one case-control and two cohort studies. According to the Newcastle-Ottawa Scale, the three studies were considered high-quality. Through this systematic review, selective serotonin reuptake inhibitors (SSRI) use during pregnancy is not significantly associated with a higher risk of developing GDM. There are still controversies about the association between serotonin and norepinephrine reuptake inhibitors (SNRI) and GDM. The use of tricyclic, tetracyclic, and atypical antidepressants by pregnant women appears to be associated with GDM. Therefore, the available information about the topic is scarce and the condition of further studies is needed.